Remede System

Respicardia Announces Highmark Coverage for the remedē® System in Patients with Central Sleep Apnea

MINNETONKA, Minn., Jan. 7, 2021 /PRNewswire/ — Respicardia, Inc., the manufacturer of the only FDA-approved active implantable system for the treatment of central sleep apnea (CSA), announced today that Highmark Blue Cross Blue Shield and its affiliates will provide coverage for the Company’s remedē® System therapy, effective immediately. Highmark provides health insurance coverage to over 5 million individuals across Pennsylvania, Delaware and West Virginia. The remedē® System “We are…